Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

valuating afatinib head-to-head versus gefitinib as a first-line treatment in EGFR M+ NSCLC patients.  Patient recruitment for this trial has recently initiated.
  • LUX-Lung 8, a Phase III trial evaluating afatinib head-to-head versus erlotinib in second-line treatment of squamous cell carcinoma of the lung.  Patient recruitment for this trial has recently initiated.
  • For more information on these trials, please visit www.clinicaltrials.gov

    About Boehringer Ingelheim in OncologyBuilding on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers.

    The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition.  Afatinib is an investigational orally-administered irreversible inhibitor of the ErbB family of receptor tyrosine kinases, which is currently in phase III clinical development in advanced NSCLC, head and neck cancer, and breast cancer.  Nintedanib (BIBF 1120) is an investigational orally-administered triple angiokinase inhibitor that targets three of the receptor tyrosine kinases shown to aid in the regulation of angiogenesis and is currently in phase III clinical development in NSCLC and ovarian cancer.  Volasertib is an investigational inhibitor of polo-like kinase that is currently being investigated in early phase trials.  Boehringer Ingelheim's oncolo
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
    (Date:12/22/2014)... 22, 2014   TRU-D SmartUVC LLC, producers ... robot, announced today that the General Services Administration has ... 2019.   This newly formed agreement will ... of government purchasers, including Department of Veteran Affairs and ... Security contacts purchasing solutions for the Ebola effort in ...
    (Date:12/22/2014)... Pa. and STOCKHOLM , ... (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced ... (CHMP) of the European Medicines Agency (EMA) has adopted ... clostridium histolyticum) for the treatment of adult men with ... of at least 30 degrees at the start of ...
    Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
    ... 2012  Verizon Enterprise Solutions, Motorola Mobility Inc. and BoxTone ... help satisfy the unique security, reliability and usability requirements ... practitioners with secure mobile devices and apps, patient care ... in near-real time to help speed decision making and ...
    ... channels are becoming increasingly plentiful in today,s environment, ... efficient performance, increase profitability and raise consumer loyalty. ... need to identify which external and internal communication ... use them. Best Practices, LLC,s ...
    Cached Medicine Technology:Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 2Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 3Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 4Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 5Effective Communication Options to Increase Organizational Effectiveness 2
    (Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
    (Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
    (Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
    (Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
    (Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
    Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
    ... BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, ... , Bank of America and Merrill Lynch 2009 ... 8:40 a.m. EDT, Bernstein,s ... 2009, 9:00 a.m. EDT, ...
    ... (Nasdaq: WCRX ) announced today that one ... ("Mayne") have filed a second lawsuit against Mylan Pharmaceuticals ... for the District of New Jersey for infringement of ... covers DORYX, a tetracycline-class oral antibiotic. The lawsuit ...
    ... better understood after taking hands-on approach , , FRIDAY, May ... specific training and tools can help young doctors do ... patients. , Seniors face added challenges with prescriptions, ... one time. Avoiding their greater susceptibility to side effects ...
    ... Award Honoring the Work of Oncology , NursesSAN ANTONIO, ... CURE magazine,s 2009 Extraordinary Healer Award for Oncology ... during a special reception at the Oncology Nursing Society,s ... patients and caregivers submitted nominations. The winner, Christine ...
    ... continues; Obama urges calm; global cases total 331 in 11 ... -- The number of confirmed swine flu cases in the ... health officials reported on Friday. , "That,s up eight states ... the U.S. Centers for Disease Control and Prevention,s science ...
    ... May 1 As the world sits on the ... attempting to reduce the ranks of personnel most skilled ... representing more than 20,000 Registered Nurses in 89 bargaining ... hospitals to reopen contracts regarding wages. In the ...
    Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Prescription Training Puts Docs in Shoes of Older Patients 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 2Health News:Swine Flu Infections Now at 141 in 19 U.S. States 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 4Health News:Swine Flu Infections Now at 141 in 19 U.S. States 5Health News:Swine Flu Infections Now at 141 in 19 U.S. States 6Health News:Swine Flu Infections Now at 141 in 19 U.S. States 7Health News:Swine Flu Infections Now at 141 in 19 U.S. States 8Health News:Swine Flu Infections Now at 141 in 19 U.S. States 9Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 2Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 3